{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:30:12Z","timestamp":1791433812020,"version":"4.3.3"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.intimp.2012.05.003","type":"journal-article","created":{"date-parts":[[2012,5,14]],"date-time":"2012-05-14T16:33:08Z","timestamp":1337013188000},"page":"408-416","source":"Crossref","is-referenced-by-count":42,"title":["MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice"],"prefix":"10.1016","volume":"13","author":[{"given":"Ming","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyou","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingli","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiesuo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2012.05.003_bb0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"10.1016\/j.intimp.2012.05.003_bb0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.smim.2010.04.007","article-title":"Adjuvants for cancer vaccines","volume":"22","author":"Dubensky","year":"2010","journal-title":"Semin Immunol"},{"issue":"25","key":"10.1016\/j.intimp.2012.05.003_bb0015","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine","volume":"361","author":"Clark","year":"2009","journal-title":"N Engl J Med"},{"issue":"50","key":"10.1016\/j.intimp.2012.05.003_bb0020","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1016\/j.vaccine.2010.09.058","article-title":"Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A\/H1N1 MF59-adjuvanted vaccine in patients with \u03b2-thalassemia major","volume":"28","author":"Esposito","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.intimp.2012.05.003_bb0025","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4161\/hv.7.6.15133","article-title":"Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A\/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome","volume":"7","author":"Esposito","year":"2011","journal-title":"Hum Vaccin"},{"issue":"37","key":"10.1016\/j.intimp.2012.05.003_bb0030","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1016\/j.vaccine.2011.06.067","article-title":"An alternative renewable source of squalene for use in emulsion adjuvants","volume":"29","author":"Brito","year":"2011","journal-title":"Vaccine"},{"issue":"11\u201312","key":"10.1016\/j.intimp.2012.05.003_bb0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.drudis.2009.02.009","article-title":"The path to a successful vaccine adjuvant\u2014\u2018the long and winding road\u2019","volume":"14","author":"O'Hagan","year":"2009","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.intimp.2012.05.003_bb0040","first-page":"320","article-title":"Rapid and frequent induction of protective immunity exceeding UK recommendations for healthcare settings by MF59-adjuvated hepatitis B vaccine","volume":"6","author":"Lewis","year":"2003","journal-title":"Commun Dis Public Health"},{"issue":"6","key":"10.1016\/j.intimp.2012.05.003_bb0045","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/655902","article-title":"Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins","volume":"202","author":"Ray","year":"2010","journal-title":"J Infect Dis"},{"issue":"9773","key":"10.1016\/j.intimp.2012.05.003_bb0050","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2012.05.003_bb0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/93.4.284","article-title":"Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine","volume":"93","author":"Harro","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"10.1016\/j.intimp.2012.05.003_bb0060","doi-asserted-by":"crossref","first-page":"13915","DOI":"10.1128\/JVI.79.22.13915-13923.2005","article-title":"Modulation of the immune response to the severe acute respiratory sundrome spike glycoprotein by gene-based and inactivated virus immunization","volume":"79","author":"Kong","year":"2005","journal-title":"J Virol"},{"issue":"29","key":"10.1016\/j.intimp.2012.05.003_bb0065","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.intimp.2012.05.003_bb0070","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1128\/JVI.73.4.3292-3300.1999","article-title":"Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance","volume":"73","author":"Verschoor","year":"1999","journal-title":"J Virol"},{"issue":"18","key":"10.1016\/j.intimp.2012.05.003_bb0075","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/S0264-410X(99)00009-2","article-title":"Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs","volume":"17","author":"O'Hagan","year":"1999","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.intimp.2012.05.003_bb0080","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s11095-009-9859-5","article-title":"MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020)","volume":"26","author":"Baudner","year":"2009","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.intimp.2012.05.003_bb0085","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.vaccine.2007.11.054","article-title":"Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice","volume":"26","author":"Wack","year":"2008","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.intimp.2012.05.003_bb0090","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-08-0526","article-title":"CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans","volume":"14","author":"Haining","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"28","key":"10.1016\/j.intimp.2012.05.003_bb0095","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","article-title":"In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study","volume":"28","author":"Brody","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.intimp.2012.05.003_bb0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1369-5274(02)00287-4","article-title":"Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity","volume":"5","author":"Wagner","year":"2002","journal-title":"Curr Opin Microbiol"},{"issue":"1","key":"10.1016\/j.intimp.2012.05.003_bb0105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/eji.200324032","article-title":"Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities","volume":"34","author":"Vollmer","year":"2004","journal-title":"Eur J Immunol"},{"issue":"17","key":"10.1016\/j.intimp.2012.05.003_bb0110","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2012.05.003_bb0115","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1172\/JCI23373","article-title":"Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909","volume":"115","author":"Speiser","year":"2005","journal-title":"J Clin Invest"},{"issue":"21","key":"10.1016\/j.intimp.2012.05.003_bb0120","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1073\/pnas.0703395104","article-title":"Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody\/Th1 responses and CD8 T cells through cross-priming","volume":"104","author":"Valmori","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.intimp.2012.05.003_bb0125","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ijc.24850","article-title":"Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival","volume":"126","author":"Karbach","year":"2010","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2012.05.003_bb0130","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1111\/j.1349-7006.2010.01732.x","article-title":"Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma","volume":"101","author":"Iwahashi","year":"2010","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.intimp.2012.05.003_bb0135","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clim.2009.01.011","article-title":"Therapeutic injection of C-class CpG ODN in draining lymph node area induces potent activation of immune cells and rejection of established breast cancer in mice","volume":"131","author":"Yang","year":"2009","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.intimp.2012.05.003_bb0140","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/eji.200535490","article-title":"Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity","volume":"36","author":"Li","year":"2006","journal-title":"Eur J Immunol"},{"issue":"26","key":"10.1016\/j.intimp.2012.05.003_bb0145","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.vaccine.2008.03.093","article-title":"Safety of MF59\u2122 adjuvant","volume":"26","author":"Schultze","year":"2008","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.intimp.2012.05.003_bb0150","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00262-010-0816-2","article-title":"Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice","volume":"59","author":"Dong","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"10.1016\/j.intimp.2012.05.003_bb0155","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","article-title":"Systemic cytokine profiles in BALB\/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants","volume":"153","author":"Valensi","year":"1994","journal-title":"J Immunol"},{"issue":"19","key":"10.1016\/j.intimp.2012.05.003_bb0160","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/S0264-410X(98)00179-0","article-title":"A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2","volume":"16","author":"Singh","year":"1998","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.intimp.2012.05.003_bb0165","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1073\/pnas.0813390106","article-title":"Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.intimp.2012.05.003_bb0170","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/eji.1830231147","article-title":"Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo","volume":"23","author":"Powrie","year":"1993","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2012.05.003_bb0175","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00262-007-0393-1","article-title":"CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged","volume":"57","author":"Sharma","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"21","key":"10.1016\/j.intimp.2012.05.003_bb0180","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.1158\/0008-5472.CAN-08-0449","article-title":"Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.intimp.2012.05.003_bb0185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/CMR.0b013e3283426805","article-title":"Autoantibodies against cell surface GRP78 promote tumor growth in a murine model of melanoma","volume":"21","author":"de Ridder","year":"2011","journal-title":"Melanoma Res"},{"issue":"5","key":"10.1016\/j.intimp.2012.05.003_bb0190","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.neo.7900054","article-title":"Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies","volume":"1","author":"Barbera-Guillem","year":"1999","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.intimp.2012.05.003_bb0195","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4049\/jimmunol.172.3.1501","article-title":"CpG-DNA aided cross-priming by cross-presenting B cells","volume":"172","author":"Heit","year":"2004","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2012.05.003_bb0200","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.4049\/jimmunol.1001869","article-title":"Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells","volume":"186","author":"Jiang","year":"2011","journal-title":"J Immunol"},{"issue":"2\u20134","key":"10.1016\/j.intimp.2012.05.003_bb0205","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000024163","article-title":"Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses","volume":"118","author":"Jakob","year":"1999","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"10.1016\/j.intimp.2012.05.003_bb0210","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1084\/jem.178.5.1655","article-title":"Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells","volume":"178","author":"Brinkmann","year":"1993","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.intimp.2012.05.003_bb0215","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.4049\/jimmunol.180.8.5402","article-title":"The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells","volume":"180","author":"Seubert","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2012.05.003_bb0220","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2567.2004.01856.x","article-title":"Type-A CpG oligonucleotides activate exclusively porcine natural interferon-producing cells to secrete interferon-alpha, tumour necrosis factor-alpha and interleukin-12","volume":"112","author":"Guzylack-Piriou","year":"2004","journal-title":"Immunology"},{"issue":"35","key":"10.1016\/j.intimp.2012.05.003_bb0225","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1016\/j.vaccine.2007.05.056","article-title":"The effectiveness of a CpG motif-based adjuvant (CpG ODN 2006) for LHRH immunization","volume":"25","author":"Conforti","year":"2007","journal-title":"Vaccine"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576912001324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576912001324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T15:18:06Z","timestamp":1713971886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576912001324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1567576912001324"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2012.05.003","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}